The Interventional Cardiology Market is projected to expand from USD 26.096 billion in 2025 to USD 34.742 billion in 2030, registering a 5.89% compound annual growth rate (CAGR).
Interventional cardiology is a minimally invasive procedure that utilizes catheters to repair damaged or weakened vessels, narrowed arteries, or other affected parts of the heart structure. Catheters are medical devices consisting of thin tubes that can be inserted into the body to serve a broad range of functions. Interventional cardiology also helps to avoid surgery with treatments like angioplasty and valve repair or replacement. The interventional cardiology market is expected to show robust during the forecast period owing to the rising adoption of minimally invasive procedures and rising incidences of cardiovascular diseases. As per data by WHO, cardiovascular diseases are the leading cause of death globally with an estimated 17.9 million people dying of CVDs in 2016. Technological advancements in interventional cardiology devices will also boost the market for interventional cardiology during the forecast period. However, stringent regulatory requirements for the approval of interventional cardiology devices might restrain the growth of the interventional cardiology market during the given time frame.
Interventional Cardiology Market Drivers:
The major players profiled in the global interventional cardiology market include Medtronic, Stryker, Abbott, B. Braun Melsungen AG, Boston Scientific Corporation, Cordis (A Cardinal Health Company), Edwards Lifesciences Corporation, GE Healthcare, Biosensors International Group, Ltd., and Biotronik, Inc. among others.
Segmentation